Please assess the completion status of the following clinical trial:

Trial Title: Epidural Nalbuphine Versus Dexmedetomidine as Adjuvants to Bupivacaine in Lower Limb Surgeries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patient acceptance.~* BMI 25-29.9 kg/m2.~* ASA I and ASA II.~* Scheduled for elective lower limb orthopedic surgeries under (CSE) block.~Exclusion Criteria:~* Patient with known allergy to study drugs,~* Patients suffering from severe chronic diseases (cardiac, renal, hepatic and neurological or diabetes),~* Patients with infection at the site of spinal-epidural block,~* Drug addict patients,~* Patients on long term steroid therapy,~* Patients with abnormalities in vertebral spine,~* Mentally retarded or uncooperative patients,~* Patients receive anti-coagulant therapy or suspected coagulopathy.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: PLACEBO_COMPARATOR): patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 2ml normal saline), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2ml normal saline).
- dexmedetomidine group (Type: ACTIVE_COMPARATOR): patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 100µg dexmedetomidine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 20µg dexmedetomidine in 2ml volume)
- nalbuphine group (Type: ACTIVE_COMPARATOR): patient will be given epidural bolus dose of 12ml (10ml 0.25% bupivacaine + 10mg nalbuphine in 2ml volume), top up dose of 8ml will be given postoperative (6ml 0.25% bupivacaine + 2mg nalbuphine in 2ml volume)

Based on this trial design, predict the completion outcome and termination type (if applicable).